Please assess the completion status of the following clinical trial:

Trial Title: Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosed with multiple myeloma by 1 of the following criteria:~  * Meets any 2 of the following major criteria:~    * Plasmacytomas on tissue biopsy~   * Bone marrow plasmacytosis (i.e., \> 30% plasma cells)~   * Monoclonal immunoglobulin spike IgG \> 3.5 g/dL or IgA \> 2.0 g/dL by serum electrophoresis; kappa or lambda light chain excretion \> 1 g by 24-hour urine protein electrophoresis~ * Plasmacytomas on tissue biopsy AND meets any 1 of the following minor criteria:~    * Presence of monoclonal immunoglobulin at a lesser magnitude than given under above major criteria~   * Lytic bone lesions~   * Normal IgM \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL~ * Monoclonal immunoglobulin spike IgG \> 3.5 g/dL or IgA \> 2.0 g/dL by serum electrophoresis; kappa or lambda light chain excretion \> 1 g by 24-hour urine protein electrophoresis AND meets 1 of the following minor criteria:~    * Bone marrow plasmacytosis (i.e., 10-30% plasma cells)~   * Lytic bone lesions~ * Presence of monoclonal immunoglobulin at a lesser magnitude than given under major criteria with bone marrow plasmacytosis (i.e., 10-30% plasma cells) AND meets 1 of the following minor criteria:~    * Lytic bone lesions~   * Normal IgM \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL~* Measurable disease, defined as a monoclonal immunoglobulin spike of ≥ 1 gm/dL by serum electrophoresis and/or a immunoglobulin spike of ≥ 200 mg by 24-hour urine protein electrophoresis or evidence of lytic bone disease OR~* Nonmeasurable disease (i.e., patients with nonsecretory or oligosecretory multiple myeloma)~* Relapsed or refractory disease~  * Relapsed disease following a response or stable disease after prior chemotherapy (e.g., single-agent steroids, vincristine, doxorubicin, and dexamethasone \[VAD\], or melphalan and prednisone \[MP\]) or high-dose chemotherapy~ * Refractory (i.e., failure to achieve at least complete or partial response or stable disease) to the most recent chemotherapy with or without systemic corticosteroids~* No plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein), and skin changes (POEMS syndrome)~* No extramedullary myeloma~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Life expectancy \> 3 months~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 75,000/mm³~* AST and ALT ≤ 3 times upper limit of normal (ULN)~* Bilirubin ≤ 2 times ULN (unless clearly related to disease)~* Creatinine clearance ≥ 30 mL/min~  * Creatinine clearance \> 15 mL/min and \< 30 mL/min due to significant myelomatous involvement of kidneys allowed at discretion of investigator~* Sodium \> 130 mmol/L~* No ECG evidence of acute ischemia or new conduction system abnormalities~* No myocardial infarction within the past 6 months~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active infection~* No severe hypercalcemia (i.e., serum calcium ≥ 14 mg/dL)~* No New York Hospital Association class III or IV heart failure~* No poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that would preclude study treatment~* No known HIV history~* No known active hepatitis B or C viral infection~* No history of allergic reaction attributable to compounds of similar chemical or biological composition to bortezomib, boron, mannitol, ethylenediaminetetramethylenephosphonic acid (EDTMP), or phosphonates~* No peripheral neuropathy \> grade 1~PRIOR CONCURRENT THERAPY:~* At least 12 weeks since prior samarium Sm 153 lexidronam pentasodium~  * No more than 1 prior treatment~* At least 24 weeks since prior strontium chloride Sr 89~  * No more than 1 prior treatment~* No major surgery within the past 4 weeks~* No chemotherapy within the past 3 weeks (6 weeks for nitrosoureas)~* No corticosteroids (\> 10 mg/day prednisone or equivalent) within the past 3 weeks~* No immunotherapy, antibody therapy, or radiotherapy (except localized radiotherapy) within the past 4 weeks~* No other concurrent investigational agents~* No concurrent corticosteroids (≥ 10 mg prednisone or equivalent)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).